Legend Biotech Corp Stock Price, News & Analysis

Legend Biotech (NASDAQ: LEGN) reported third quarter 2025 results on November 12, 2025, highlighting CARVYKTI net trade sales of ~$524 million and updated U.S. and EC labels to include an overall survival (OS) benefit from CARTITUDE-4. The company reported cash and time deposits of ~$1.0 billion as of September 30, 2025 and has treated over 9,000 patients to date. Legend initiated commercial production at its Tech Lane facility in Ghent and expects CARVYKTI profitability by year-end and company-wide profitability in 2026.

Legend Biotech (NASDAQ: LEGN) announced 10 presentations at the 67th ASH Annual Meeting, Dec 6-9, 2025 in Orlando.

The program includes two oral and seven poster presentations on CARVYKTI (ciltacabtagene autoleucel) for multiple myeloma and an oral presentation of first-in-human Phase 1 data for Lucar-G39D, an allogeneic anti-CD20/CD19 dual-CAR gamma delta T cell therapy for relapsed/refractory B-cell NHL.

CARVYKTI is noted as commercially available in 14 countries and used to treat more than 9,000 patients to date.

Legend Biotech (NASDAQ: LEGN) will host a live investor conference call and webcast at 8:00 AM ET on Wednesday, November 12, 2025 to review third quarter 2025 results. Senior leaders will provide an overview of the company’s performance for the quarter.

Investors can join the live audio webcast via the company weblink. A replay of the webcast and the earnings news release will be posted in the Investor Relations site under Events and Presentations approximately two hours after the call concludes.

Legend Biotech (NASDAQ: LEGN), a global cell therapy leader, has announced its participation in the upcoming Morgan Stanley Global Healthcare Conference. The company's CEO, Dr. Ying Huang, will engage in a fireside chat on September 9, 2025, at 4:05 p.m. ET in New York.

Investors can access the live webcast through Legend Biotech's Investor Relations website section, with a replay becoming available approximately 48 hours after the event.

Legend Biotech (NASDAQ: LEGN) has appointed Carlos Santos as its new Chief Financial Officer, effective immediately. Santos, who brings extensive experience from pharmaceutical and technology sectors, joins from AstraZeneca where he served as CFO for US Oncology. He succeeds Jessie Yeung, who has been interim CFO since January 2025.

In his new role, Santos will oversee Legend's financial operations with a focus on maintaining a strong balance sheet and achieving profitability. The company aims to reach companywide profitability in 2026, driven by the success of their CAR-T cell therapy franchise, CARVYKTI®.

Legend Biotech (NASDAQ: LEGN) reported strong Q2 2025 results, highlighted by CARVYKTI® net trade sales of $439 million, marking the strongest quarterly performance of any CAR-T therapeutic to date. The company announced groundbreaking five-year CARTITUDE-1 study results showing one-third of multiple myeloma patients remaining progression-free.

Financial highlights include $1.0 billion in cash and equivalents, license revenue of $35.3 million, and collaboration revenue of $219.7 million. The company achieved an adjusted net income of $10.1 million, compared to a $2.5 million loss in Q2 2024. Legend Biotech anticipates reaching operating profitability in 2026.

The company has treated over 7,500 clinical and commercial patients to date and presented promising data for new solid tumor therapies LB2102 and LB1908 at ASCO 2025.

Legend Biotech (NASDAQ: LEGN), a global cell therapy leader, has scheduled an investor conference call for Monday, August 11, 2025, at 8:00 am ET to discuss their second quarter 2025 financial results. The company's senior leadership will present the quarterly performance overview during the call.

Investors can access the live audio webcast through a provided weblink. Following the call, both the webcast replay and earnings release will be accessible on Legend Biotech's website in the Investor Relations section under Events and Presentations, approximately two hours after the call's conclusion.

Legend Biotech announced groundbreaking 5-year survival data for CARVYKTI in multiple myeloma treatment at ASCO 2025. In the CARTITUDE-1 study, 33% of heavily pretreated relapsed/refractory multiple myeloma patients remained progression-free for 5+ years after a single CARVYKTI infusion. The study showed median overall survival of 60.7 months, with 32 of 97 patients progression-free without additional treatment. CARTITUDE-4 subgroup analyses demonstrated CARVYKTI's superior efficacy versus standard therapies across various patient groups. The company also presented promising early results from Phase 1 studies of LB1908 in gastroesophageal cancers and LB2102 in lung cancers, showcasing potential in solid tumors. Over 6,500 patients have been treated with CARVYKTI to date, marking it as the first CAR T-cell treatment in multiple myeloma to show overall survival benefit versus standard care.

Legend Biotech (NASDAQ: LEGN) announced new data presentations at ASCO, EHA, and ASGCT conferences showcasing developments in their oncology portfolio. CARVYKTI®, their lead CAR-T therapy for multiple myeloma, demonstrated impressive long-term results with patients remaining alive and progression-free for over 5 years after a single infusion in the CARTITUDE-1 study. The company has treated over 6,500 patients with CARVYKTI® to date. Additionally, CARTITUDE-4 study data showed improved survival rates compared to standard care in key subgroups. Legend will also present preliminary Phase 1 results for two pipeline candidates: LB2102 for lung cancers (licensed to Novartis) and LB1908 for gastroesophageal cancers, marking important progress in expanding cell therapy into solid tumors.